Glaxo Group Limited

Smithkline Beecham Corporation

Glaxosmithkline Intellectual Property Development Limited

Eukarion, Inc.

Ian B Campbell

Alan Naylor

Harry Finch

Lawrence H Lunts

Ian F Skidmore

Paul John Beswick

Simon John Fawcett MacDonald

John Martin Pritchard

Panayiotis Alexandrou Procopiou

Niall Andrew Anderson

Ashley Paul Hancock

Matthew Howard James Campbell-Crawford

Neil Mathews

Charles Willbe

Seble Lemma

Philip Charles Box

Ann Louise Walker

George Edward Tranter

Gerard Martin Paul Giblin

John W Clitherow

John Bradshaw

Diane Mary Coe

Peter C North

David Middlemiss

Anthony William James Cooper

William L Mitchell

Neil Anthony Pegg

Stephen Swanson

James Michael Woolven

Gordon G Weingarten

Graham George Adam Inglis

Daniel Terence Tape

Simon Peace

Charanjit Bountra

Iain McFarlane McLay

Philip Alan Skone

Brian D Judkins

Paul Francis Lambeth

Robert Charles Wheeler

Heather Anne Barnett

Haydn Terence Jones

Steven Philip Keeling

Neil Matthews

A compound of formula (I) or a salt thereof: wherein Rrepresents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono- or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected from a hydrogen atom, a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when Rrepresents an N-linked mono- or di-substituted pyrazole, Rdoes not represent 3,5-Dimethyl-1H-pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1-yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H-pyrazol-1-yl or 1H-pyrazol-1-yl.

Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases

A compound of formula (I) or a salt thereof: wherein Rrepresents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono- or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when Rrepresents an N-linked mono- or di-substituted pyrazole, Rdoes not represent 3,5-Dimethyl-1H-pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1-yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H-pyrazol-1-yl or 1H-pyrazol-1-yl.

Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases

The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, processes for their preparation, pharmaceutical compositions containing these compounds, and their use in the treatment of allergic disorders, such as allergic rhinitis and asthma.

Bicyclic imidazole as DP1 receptor antagonists

The present invention provides compounds of formula (I): a process for their preparation, to pharmaceutical compositions comprising the compounds and the preparation of said compositions, to intermediates and to use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation, allergy and/or autoimmune conditions.

Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions

The invention provides the compounds of formula (I)and pharmaceutically acceptable derivatives thereof wherein: Compounds of formula (I) are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever, inflammation of a variety of conditions and diseases.

Pyrazolopyridine derivatives as selective cox-2 inhibitors

The invention provides a pharmaceutical composition comprising a compound of formula (I)or a pharmaceutically acceptable salt, solvate, ester or salt or solvate of such ester, of a compound of formula (I) in which:

2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors

2,3-diaryl-pyrazolo&lsqb;1,5-B&rsqb;pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors

Bipyridine manganese complexes

Pyrazolopyridines

The invention provides the compounds of formula (I) and pharmaceutically acceptable derivatives thereof in which: R is halogen, C alkyl, C alkoxy, C alkoxy substituted by one or more fluorine atoms, or O(CH ) NR R ; R and R are independently selected from H, C alkyl, C alkyl, substituted by one or more fluorine atoms, C alkoxy, C hydroxyalkyl, SC alkyl, C(O)H, C(O)C alkyl, C alkylsulphonyl, C alkoxy substituted by one or more fluorine atoms, O(CH ) CO C alkyl, O(CH ) SC alkyl, (CH ) NR R , (CH ) SC alkyl or C(O)NR R ; with the proviso that when R is at the 4-position and is halogen, at least one of R and R is C alkylsulphonyl, C alkoxy substituted by one or more fluorine atoms, O(CH ) CO C alkyl, O(CH ) SC alkyl, (CH ) NR R or (CH ) SC alkyl, C(O)NR R ; R is C alkyl or NH ; R and R are independently selected from H, or C alkyl or, together with the nitrogen atom to which they are attached, form a 4-8 membered saturated ring; and n is 1-4. Compounds of formula (I) are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever, inflammation of a variety of conditions and diseases.

2,3-Diaryl-pyrazolo&lsqb;1,5-b&rsqb;pyridazines derivatives, their preparation and their use as cyclooxygenase 2(COX-2) inhibitors

Compounds and methods of preparing compounds represented by structural formula (I):

The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt or solvate thereof wherein R.sup.1 represents a halogen or hydrogen atom or a C.sub.1-6 alkyl or C.sub.1-6 alkoxy group;

Benzanilide derivatives

The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts and solvates thereof; wherein;

Phenethandamine derivatives and pharmaceutical use thereof

The invention provides compounds of the general formula (I) ##STR1## wherein X represents a C.sub.1-6 alkylene, C.sub.2-6 alkenylene or C.sub.2-6 alkynylene chain and

Dichloroaniline derivatives for the therapy or prophylaxysis of a

The invention provides compounds of the general formula ##STR1## and physiologically acceptable salts and solvates thereof, wherein Z represents the group ##STR2## where A represents a group selected from HOR.sup.3 --, R.sup.6 NH(CH.sub.2)p--, R.sup.10 R.sup.11 N--, R.sup.12 OCH.sub.2 --, CH.sub.3 SO.sub.2 CH.sub.2 -- or NCCH.sub.2 --;

Ethanolamine derivatives

Growing community of inventors

Dane End, United Kingdom

Ian B Campbell